In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LFB Biotechnologies SAS

Division of LFB SA

Latest From LFB Biotechnologies SAS

Chronic Lymphocytic Leukemia Market To Grow Despite Biosimilar Wave

The chronic lymphocytic leukemia market is set to increase in size over the next decade despite an anticipated influx of biosimilars, new research by Datamonitor Healthcare finds. AbbVie/J&J's Imbruvica will remain the leading product, but the need for safe and effective therapies for relapsed and refractory CLL patients remains.

Analysis Cancer

TG Therapeutics Builds A Business Model For Today

The speed with which TG Therapeutics burst on the scene, along with the impressive potency and safety of its novel combinations of cancer drugs, has perhaps blinded observers to the unique business model that has carried it this far.

BioPharmaceutical Strategy

TG Therapeutics prices $32.5m public offering

New York-based TG Therapeutics has priced a public offering of 5.7 million shares of common stock at $6.15 per share in a bid to raise $32.5m to fund the development of its two clinical candidates.

Cancer Companies

Thallion attempts to tame Jaguar ahead of Bellus acquisition vote

Canadian firm Thallion Pharmaceuticals will hold a shareholder meeting on 6 August to vote on the proposed acquisition of Thallion by Bellus Health. Thallion's board is keen for the deal to proceed, but its largest single shareholder, Jaguar Financial which holds 10.1%, has indicated it will vote against the deal unless terms are increased.

Metabolic Disorders Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Immune Disorders
  • Alias(es)
  • LFB Biotechnologies
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • LFB SA
  • Senior Management
  • Contact Info
  • LFB Biotechnologies SAS
    Phone: (33) 69 82 70 10
    3, avenue des Tropiques B.P. 305
    Les Ulis
    Courtabeuf Cedex , 91958